All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pembrolizumab Plus Chemotherapy Does Not Significantly Affect QOL in PD-L1+ TNBC

May 6th 2022

The addition of pembrolizumab to chemotherapy led to significant survival benefits without substantial deterioration in health-related quality of life among patients with treatment-naïve, PD-L1–positive advanced triple-negative breast cancer according to results from the phase 3 KEYNOTE-355 trial.

Evidence Grows to Support Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer and Active Brain Metastases

May 6th 2022

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

Alpelisib Plus Endocrine Therapy Yields Similar PFS Benefits in Subgroup Analysis of PIK3CA-Mutated, HR+ Breast Cancer

May 6th 2022

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL

May 6th 2022

The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.

Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer

May 6th 2022

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.

John Theurer Cancer Center Treats First Patient in U.S. With Investigational Drug for Brain Cancer

May 6th 2022

John Theurer Cancer Center at Hackensack University Medical Center in Hackensack has treated the first patient in the country with an investigational new drug for relapsed glioblastoma and other anaplastic gliomas.

Data-Driven Health Economics Research Can Improve Clinical, Economic Outcomes

May 6th 2022

Data-driven health economics and outcomes research offers clinicians effective methods for improving quality of life and outcomes for patients and optimizing economic benefits for the practice.

Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer

May 6th 2022

Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population.

Sacituzumab Govitecan Maintains Clinical Benefit Across HER2 Expressions in TNBC

May 5th 2022

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.

Sylvester Researcher Receives Two Grants to Pursue Pediatric Immunotherapies

May 5th 2022

The Pillai lab will explore off-the-shelf, innate natural killer T cell immunotherapies that can be targeted against challenging tumors.

Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

May 5th 2022

The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.

Maintained Survival Benefit Supports Frontline Ribociclib/Fulvestrant Combo in Advanced HR+ Breast Cancer

May 5th 2022

The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Genomic Testing Challenges Persist

May 5th 2022

Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice.

CTX-009/Paclitaxel Combo Demonstrates Antitumor Activity, Favorable Tolerability in Biliary Tract Cancer

May 5th 2022

A novel combination comprised of the investigational bispecific antibody CTX-009 and paclitaxel was found to produce responses in 4 subtypes of biliary tract cancer with favorable safety and tolerability, according to interim results from an ongoing phase 2 trial.

DESTINY-Breast03 Could Have Long-Lasting Effects on the Treatment Landscape of HER2+ Breast Cancer

May 5th 2022

Marcela Mazo Canola, MD, discusses pivotal trials in early-stage and metastatic HER2-positive breast cancer, plus ongoing trials to watch.

FDA Grants Regular Approval to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer

May 4th 2022

The FDA has approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.

CG0070 Plus Nivolumab Under Investigation in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

May 4th 2022

The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.

FDA Grants Fast Track Status to HM43239 for FLT3-Mutated, Relapsed/Refractory AML

May 4th 2022

The FDA has granted a fast track designation to the myeloid kinome inhibitor, HM43239, for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia whose tumors harbor a FLT3 mutation.

Diverse Enrollment in Clinical Trials is Crucial to Address Disparities and Improve Cancer Care

May 4th 2022

Ruben A. Mesa, MD, discusses the different disparities that are known to affect cancer care and key efforts being made to address them.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 4th 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.